NCT06653972View on ClinicalTrials.gov

Efficacy and Safety of a Two-week Dosing Regimen of Vinorelbine Combined with Liposomal Doxorubicin in the Treatment of HER2-negative Advanced Breast Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

February 1, 2026

Study Completion Date

September 30, 2026

Conditions
Her2-negative Metastatic Breast CancerVinorelbineLiposomal Doxorubicin
Interventions
DRUG

Pegylated Liposomal Doxorubicin + vinorelbine,every cycle is 14d.

Pegylated Liposomal Doxorubicin 25mg/m2 ivgtt d1 + vinorelbine25mg/m2 ivgtt d1/q14d.

All Listed Sponsors
collaborator

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER

lead

Wang Jiayu

OTHER

NCT06653972 - Efficacy and Safety of a Two-week Dosing Regimen of Vinorelbine Combined with Liposomal Doxorubicin in the Treatment of HER2-negative Advanced Breast Cancer | Biotech Hunter | Biotech Hunter